title: The oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin inhibits effects of the 5-HT1A receptor agonist 8-OH-DPAT on plasma levels of insulin, cholecystokinin and somatostatin.
abstract: The aim of the present study was to investigate whether the 5-HT1A receptor agonist 8-OH-DPAT, which previously has been shown to release oxytocin, also influences plasma levels of gastrointestinal and pancreatic hormones, and if so, whether such an effect is mediated by an oxytocinergic mechanism. For this purpose 8-OH-DPAT (0.5 mg/kg s.c.) was injected to male rats pretreated with the oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin (1 mg/kg s.c.), or vehicle. Thirty min after injection of 8-OH-DPAT, plasma levels of oxytocin were significantly increased. 8-OH-DPAT also increased insulin and decreased CCK and somatostatin levels, effects that were blocked by pretreatment with the oxytocin antagonist. Taken together, these data suggest that the effect of 8-OH-DPAT on plasma levels of insulin, somatostatin and CCK may be mediated by oxytocin. In previous experiments, we have shown that following i.c.v. application of oxytocin, plasma levels of insulin are increased through a cholinergic mechanism. In this study, 2 ng of oxytocin decreased plasma levels of CCK, gastrin and somatostatin, effects that were blocked by pretreatment with atropine. Since oxytocinergic fibers which originate in the PVN project to the DMX, we suggest that the effect on the release of insulin, CCK and somatostatin induced by the 5 HT1A receptor agonist 8-OH-DPAT may be mediated by an oxytocinergic activation of a vagal mechanism.
authors.affiliation: Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Björkstrand
authors.forename: S
authors.initials: S
authors.lastname: Ahlénius
authors.forename: U
authors.initials: U
authors.lastname: Smedh
authors.forename: K
authors.initials: K
authors.lastname: Uvnäs-Moberg
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology*; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002766:Cholecystokinin / Q000097:blood / Q000187:drug effects* / Q000276:immunology; D005755:Gastrins / Q000097:blood / Q000187:drug effects / Q000276:immunology; D007106:Immune Sera / Q000276:immunology; D007328:Insulin / Q000032:analysis / Q000097:blood / Q000276:immunology / Q000378:metabolism*; D007457:Iodine Radioisotopes; D008297:Male; D010121:Oxytocin / Q000097:blood / Q000187:drug effects / Q000276:immunology; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D018045:Receptors, Oxytocin / Q000037:antagonists & inhibitors*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D013004:Somatostatin / Q000097:blood / Q000187:drug effects* / Q000276:immunology; D014668:Vasotocin / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D005755:Gastrins; D007106:Immune Sera; D007328:Insulin; D007457:Iodine Radioisotopes; D018045:Receptors, Oxytocin; D017366:Serotonin Receptor Agonists; C047046:atosiban; D010121:Oxytocin; D013004:Somatostatin; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D001285:Atropine; D002766:Cholecystokinin; D014668:Vasotocin